儿童血浆可溶性尿激酶纤溶酶原激活物受体(suPAR)与CKD进展
本研究为前瞻性纵向队列,纳入565例1-16岁CKiD研究患儿,按血浆suPAR四分位分组,随访6个月。结果显示最高四分位组较低四分位组CKD进展风险快54%(P<0.001),调整eGFR后仍快33%(P=0.008)。提示高suPAR水平与儿童CKD进展相关。
要点
- 儿童CKD患者中,最高suPAR四分位组进展风险较低四分位组快54%。
- 调整eGFR后,最高四分位组进展风险仍快33%(P=0.008)。
- 血浆suPAR水平在6个月内变化小,可作为稳定生物标志物。
核心结论
- 较高suPAR水平与儿童CKD患者更短的肾脏替代治疗或eGFR减半时间相关。
研究设计与样本
- 前瞻性纵向队列研究,纳入565例1-16岁CKiD研究参与者,测量基线和6个月时血浆suPAR。
主要发现
- 最高suPAR四分位组较低四分位组CKD进展快54%(P<0.001)。
- 模型加入eGFR后,最高四分位组进展仍快33%(P=0.008)。
- 血浆suPAR水平6个月内变化小。
关键数值与推荐
- CKD进展定义为开始肾脏替代治疗(透析或移植)或eGFR下降>50%。
- suPAR按四分位分类,使用对数正态生存模型调整混杂因素。
临床怎么用
- 血浆suPAR或可作为儿童CKD进展风险评估的辅助生物标志物,但需进一步验证。
局限性
- 可能存在残余混杂,观察性数据,高eGFR亚组患者较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Soluble urokinase plasminogen activator receptor (suPAR) is a novel biomarker associated with incident chronic kidney disease (CKD) and has been identified as an independent risk factor for CKD progression in children, although these findings remain preliminary, limited to a single point in time, and unreplicated in pediatric cohorts. STUDY DESIGN: Prospective longitudinal cohort study. SETTING & PARTICIPANTS: 565 participants aged 1 to 16 years enrolled in the Chronic Kidney Disease in Children (CKiD) Study. EXPOSURE: Plasma suPAR levels, categorized by quartiles, measured at study entry and a 6-month follow-up interval. OUTCOME: CKD progression, defined as the initiation of kidney replacement therapy (dialysis or transplantation) or >50% decline in estimated glomerular filtrate rate (eGFR). ANALYTIC APPROACH: Associations between plasma suPAR quartiles and risk for CKD progression were estimated using lognormal survival models, adjusting for potential confounders. RESULTS: Participants in the highest suPAR quartile experienced 54% faster progression compared with the lowest quartile after adjustment for demographic and traditional CKD risk factors (P < 0.001). Addition of eGFR to the model attenuated the risk, although those in the highest quartile experienced 33% faster progression compared with the lowest quartile (P = 0.008). Plasma suPAR levels showed little change over 6 months. LIMITATIONS: Potential for residual confounding, reliance on observational data, relatively fewer patients with higher eGFRs for subgroup analysis. CONCLUSIONS: Higher suPAR levels are associated with shorter time to kidney replacement therapy or halving of eGFR in children with CKD. This association is attenuated slightly with inclusion of eGFR in regression modeling but remains a significant association for participants with the highest suPAR levels.
引用
- Weidemann DK, Abraham AG, Roem JL, et al. Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children. Am J Kidney Dis. 2020. PMID: 31987488. doi:10.1053/j.ajkd.2019.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。